IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
Authors:
- Sven H. LoosenSLSven H. Loosen
- Maximilian Schulze-HagenMSMaximilian Schulze-Hagen
- Catherine LeyhCLCatherine Leyh
- Fabian BenzFBFabian Benz
- Mihael VucurMVMihael Vucur
- Christiane KuhlCKChristiane Kuhl
- Christian TrautweinCTChristian Trautwein
- Frank TackeFTFrank Tacke
- Philipp BrunersPBPhilipp Bruners
- Christoph RoderburgChristoph Roderburg
- Tom LueddeTLTom Luedde
Open Access
- 14 June 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (6) , 1766
Abstract
While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases. However, it is still not fully understood which patients particularly benefit from TACE. Cytokines represent a broad category of signaling molecules that might reflect concomitant inflammation as an adverse prognostic factor. Here, we evaluated the role of interleukin (IL)-6, IL-8, and CC-chemokine ligand (CCL)22 as biomarkers in the context of TACE treatment. Cytokine serum levels were analyzed by multiplex immunoassay in 54 patients (HCC: n = 44, liver metastases: n = 10) undergoing TACE as well as 51 healthy controls. Patients with primary and secondary liver cancer showed significantly elevated levels of IL-6 and IL-8 but not CCL22 compared to healthy controls. Interestingly, low pre-interventional levels of IL-6 and IL-8 were predictors for an objective response after TACE in binary logistic regression. In contrast, patients with high pre-interventional IL-6 and IL-8 serum levels not only poorly responded to TACE but had a significantly impaired overall survival. Serum levels of IL-6 and IL-8 represent promising biomarkers for patients undergoing TACE and might help to pre-interventionally identify patients who particularly benefit from TACE regarding objective treatment response and overall survival.Keywords
This publication has 34 references indexed in Scilit:
- Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta‐analysisHepatology, 2017
- Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolizationPLOS ONE, 2017
- Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a reviewJournal of Hepatocellular Carcinoma, 2017
- Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosisAbdominal Radiology, 2017
- Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting DataSeminars in Interventional Radiology, 2017
- Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory DiseasesTheranostics, 2017
- Multidisciplinary approach of colorectal cancer liver metastasesWorld Journal of Clinical Oncology, 2017
- Transarterial chemoembolization (TACE) for colorectal liver metastases—current status and critical reviewLangenbeck's Archives of Surgery, 2015
- Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction modelLiver International, 2015
- Chemokines and Chemokine Receptors: Their Manifold Roles in Homeostasis and Disease2004